Exebacase cf-301
WebSep 6, 2024 · "We are very pleased to have completed enrollment of this Phase 2 superiority study, which is a major milestone in the development of exebacase (CF-301) as a potential new treatment option for patients with Staph aureus bacteremia including endocarditis. We thank the investigators, study sites and patients for their ongoing participation ... WebMar 3, 2024 · “Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid (HSF) against biofilm-forming Staphylococcus epidermidis (S. epidermidis) isolates.” in European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). April 13–16; Amsterdam, Netherlands. Google Scholar.
Exebacase cf-301
Did you know?
WebDec 1, 2024 · Exebacase (lysin CF-301) is a potent antistaphylococcal lysin, with distinguishing features that include a low propensity for resistance, synergy with … WebJan 25, 2024 · Exebacase (CF-301) being developed by ContraFect Corporation is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of ...
WebExebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for … Our lead lysin, exebacase (CF-301) is an investigational product candidate that … Exebacase (CF-301) Exebacase is a novel, investigational lysin with potent activity … Exebacase (CF-301) Exebacase is a novel, investigational lysin with potent activity … Gary Woodnutt, Ph.D. Senior Vice President of Translational Sciences and … Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus … Roger J. Pomerantz, M.D., F.A.C.P. President, Chief Executive Officer and … About Contrafect Corporation. We are focused on developing first-in-class … Overview. Our therapeutic product candidates are direct lytic agents (DLAs) … Company Overview. ContraFect is a clinical-stage biotechnology company … Address: 28 Wells Avenue 3rd Floor Yonkers, NY 10701 US. Telephone: 914 … WebJun 17, 2024 · About Exebacase (CF-301): Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus , a …
WebAug 28, 2024 · Presentation Title: Development of Exebacase (Lysin CF-301), a Direct Lytic Agent with Potent Activity Against Staphylococcus aureus Speaker: Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development Session: The Road from Pre-Clinical to Clinical for Non-Traditional Therapies WebFeb 10, 2024 · CF-301, also known as Exebacase is ContraFect's lead program. CF-301 was discovered in the laboratory of Dr. Vincent Fischetti and has been licensed from Rockefeller University. Lysins are ...
WebOct 26, 2024 · Exebacase has been granted Breakthrough Therapy designation for the treatment of MRSA bloodstream infections by the U.S. Food and Drug Administration (FDA). The Company is providing expanded access to exebacase under a treatment protocol available to clinical sites participating in the ongoing Phase 3 study, which enables …
WebMay 14, 2024 · Lysin exebacase (CF-301) is an anti-staphylococcal lysin with potent bactericidal activity against S. aureus and additionally against coagulase-negative … session encryption is requiredWebFeb 17, 2024 · Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including … the the black phoneWebMar 3, 2024 · Exebacase (CF-301) belongs to a novel class of protein-based antibacterial agents, called lysins (peptidoglycan hydrolases). Exebacase exhibits potent antistaphylococcal activity and is the first lysin to initiate clinical trials in the United States. To support clinical development, the potential for resistance development to exebacase was ... the theblaze